As a specialty therapeutics, preclinical-stage biotech company, Inversago Pharma develops new generations of peripherally-acting cannabinoid-1 receptor (CB1) inverse agonists for the treatment of Prader-Willi Syndrome, non-alcoholic steatohepatitis (NASH), type 1 diabetes and other metabolic disorders such as diabetic nephropathy. The mechanism of action of Inversago’s molecules addresses the safety limits associated to firs...
As a specialty therapeutics, preclinical-stage biotech company, Inversago Pharma develops new generations of peripherally-acting cannabinoid-1 receptor (CB1) inverse agonists for the treatment of Prader-Willi Syndrome, non-alcoholic steatohepatitis (NASH), type 1 diabetes and other metabolic disorders such as diabetic nephropathy. The mechanism of action of Inversago’s molecules addresses the safety limits associated to first generation, centrally-acting CB1 blockers, allowing the company to exploit their full medical potential.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.